A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Boehringer Ingelheim
Boehringer Ingelheim
National Cancer Institute (NCI)
Stanford University
University of Colorado, Denver
Johnson & Johnson Enterprise Innovation Inc.
Exelixis
University of California, Davis
Kivu Bioscience Inc.
Vanderbilt-Ingram Cancer Center
EpiBiologics
Fox Chase Cancer Center
AstraZeneca
Emory University
Dana-Farber Cancer Institute
Arcus Biosciences, Inc.
R-Pharm
Radiopharm Theranostics, Ltd
Seagen Inc.
Bayer
Pfizer
Pfizer
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Novartis
Genentech, Inc.
ALX Oncology Inc.
AbbVie
Clasp Therapeutics, Inc.
Normunity AccelCo, Inc.
Eli Lilly and Company
Poseida Therapeutics, Inc.
Baylor College of Medicine
MacroGenics
Ohio State University Comprehensive Cancer Center
SystImmune Inc.
NYU Langone Health
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Boundless Bio, Inc.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Seagen Inc.
Eli Lilly and Company
Qilu Pharmaceutical Co., Ltd.
Royal Marsden NHS Foundation Trust
Boehringer Ingelheim
AbbVie
VLP Therapeutics
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Pfizer